This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Updated on 15/03/2018

HIV

MSD’s Commitment to HIV: 30 years and counting

MSD’s Commitment to HIV: 30 years and counting

This video contains information on MSD’s journey with HIV care, with over 9 years of real-world patient experience,1 Isentress® (raltegravir), the first integrase inhibitor,2,3 still has many reasons to be the first- choice third agent: its efficacy and tolerability profiles, convenience and low drug-drug interaction potential.4-7

Useful links

British HIV Association (BHIVA) Clinical guidelines
BHIVA guidelines for the management of HIV infection

European AIDS Clinical Society (EACS) guidelines
EACS European guidelines for treatment of HIV-infected adults in Europe

DHHS treatment guidelines
US DHHS guidelines on the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

World Health Organisation (WHO) guidelines
WHO guidelines on the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

International Antiviral Society - USA (IAS-USA) guidelines
International Antiviral Society–USA practice guidelines for treatment of HIV-infected adults

SMC recommendation
SMC recommendation for ISENTRESS (raltegravir)

All Wales Medicines Strategy Group recommendation
AWMSG recommendation for Isentress (raltegravir)

Find out more about ISENTRESS® (raltegravir)

References

  1. ISENTRESS Summary of Product Characteristics.
  2. MSD Newsroom. MSD Newsroom Webpage 2017. Available at http://www.mrknewsroom.com/news-release/corporate-news/merck-marks-30-year-milestone-commitment-innovation-and-care-hivaids(accessed September 2017).
  3. Zelalem Temesgen. Raltegravir: first in class HIV integrase inhibitor Therapeutics and Clinical Risk Management. 2008;4(2): 493-500.
  4. J.L. Lennox. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1 Ann Intern Med 2014;2014;161: 4610471.
  5. Cahn P et al. Raltegravir (RAL) 1200 mg once daily (QD) is non-inferior to RAL 400 mg twice daily (BID), in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects: week 48 results AIDS 2016 Oral Abstract 2016;FRAB0103LB: 1.
  6. Rizk ML, Houl R, Chan GH, et al. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation Antimicrob Agents Chemother 2014;58(3): 1294-1301.
  7. Liverpool HIV Drug Interactions. Liverpool HIV Drug Interactions Webpage 201. Available at http://www.hiv-druginteractions.org/checker (accessed September 2017).

Supporting documentation

ISENTRESS 400 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

ISENTRESS 600 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

INFC-1246455-0000 | Date of Preparation: March 2018